Is Trikafta approved by the FDA?

Yes, Trikafta is FDA approved. Trikafta, a combination of elexacaftor, ivacaftor, and tezacaftor, was approved by the U.S. Food and Drug Administration (FDA) on October 21, 2019. This medication is a significant advancement in the treatment of cystic fibrosis (CF), a genetic disorder that affects the lungs and digestive system.

What is Trikafta?

Trikafta is a combination drug consisting of three active ingredients: elexacaftor, ivacaftor, and tezacaftor. It falls under the drug class known as CFTR modulators, which target the defective CFTR protein responsible for cystic fibrosis.

How Does Trikafta Work?

The three components of Trikafta work synergistically to improve the function of the defective CFTR protein.

• Elexacaftor and Tezacaftor: These help to increase the amount of CFTR protein on the cell surface.
• Ivacaftor: This improves the function of the CFTR protein once it reaches the cell surface.

Indications for Use

Trikafta is indicated for the treatment of cystic fibrosis in patients aged 2 years and older who have at least one F508del mutation in the CFTR gene. This mutation is the most common cause of cystic fibrosis.

Dosage and Administration

Trikafta is available in the form of oral granules and tablets.

• Administration: The medication should be taken twice daily, once in the morning and once in the evening, with fat-containing food to enhance absorption.
• Dosage: The dosage varies based on age and weight. For children and teenagers under 12 years old, the dosage is adjusted according to their weight.

Side Effects

Common side effects of Trikafta include:

• Headache
• Diarrhea
• Stomach pain
• Rash
• Abnormal laboratory tests
• Flu-like symptoms (fever, chills, body aches)
• Cold-like symptoms (stuffy nose, sinus pain, sneezing, sore throat)

Serious side effects can occur, including vision changes and liver problems. Patients are advised to seek immediate medical attention if they experience any signs of an allergic reaction or liver issues.

Warnings and Precautions

• Allergies: Patients should inform their healthcare provider if they have any known allergies to the components of Trikafta.
• Liver and Kidney Disease: Those with a history of liver or kidney disease should consult their doctor before starting Trikafta.
• Pregnancy and Breastfeeding: The effects of Trikafta on pregnant or breastfeeding women are not well understood. It is important to discuss potential risks and benefits with a healthcare provider.

Drug Interactions

Certain medications can interact with Trikafta, potentially affecting its efficacy or increasing side effects. Notable interactions include:

• Antibiotics (e.g., clarithromycin, erythromycin)
• Antifungal medications (e.g., fluconazole, ketoconazole)
• Seizure medications (e.g., carbamazepine, phenobarbital)
• St. John’s wort

Patients should provide a complete list of their current medications to their healthcare provider to avoid potential interactions.

Conclusion

Trikafta is a groundbreaking medication for the treatment of cystic fibrosis, approved by the FDA on October 21, 2019. It has significantly improved the quality of life for many individuals with cystic fibrosis by targeting the underlying cause of the disease. As with any medication, it is important to use Trikafta under the guidance of a healthcare professional to manage potential side effects and interactions effectively.

How to obtain the latest development progress of all drugs?

In the Synapse database, you can stay updated on the latest research and development advances of all drugs. This service is accessible anytime and anywhere, with updates available daily or weekly. Use the "Set Alert" function to stay informed. Click on the image below to embark on a brand new journey of drug discovery!